Ceritinib – Uses, Dosage, Side Effects, Interaction Ceritinib is an orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins, and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types. Ceritinib is a small molecule tyrosine kinase receptor inhibitor and antineoplastic agent that is used in the therapy of selected forms of advanced non-small cell lung cancer (NSCLC). Ceritinib is associated with a moderate rate of serum aminotransferase elevations during therapy and rare instances of clinically apparent acute liver injury. Ceritinib is a member of the class of amino pyrimidines that is 2,6-diamino-5-fluoropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methyl phenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer. It has a role as an antineoplastic agent and an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It is an aminopyrimidine, an aromatic ether, an organochlorine compound, a secondary amino compound, a member of piperidines, and a sulfone. Mechanism of Action Ceritinib inhibits Anaplastic lymphoma kinase (ALK) also known as ALK tyrosine kinase receptor or CD246 (cluster of differentiation 246), which is an enzyme that in humans is encoded by the ALK gene. About 4-5% of NSCLCs have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells. Ceritinib has been shown to inhibit in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins and demonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice and rats. or Ceritinib is a tyrosine kinase inhibitor that selectively and potently inhibits anaplastic lymphoma kinase (ALK). In normal physiology, ALK functions as a key step in the development and function of nervous system tissue. However, chromosomal translocation and fusion give rise to an oncogenic form of ALK that has been implicated in the progression of NSCLC. Ceritinib thus acts to inhibit this mutated enzyme and stop cell proliferation, ultimately halting cancer progression.[rx] Because ceritinib is considered a targeted cancer therapy, an FDA-approved test is required to determine which patients are candidates for ceritinib. This test, developed by Roche, is the VENTANA ALK (D5F3) CDx Assay and is used to identify ALK-positive NSCLC patients who would benefit from ceritinib treatment.[rx] Indications Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Ceritinib is a small molecule tyrosine kinase receptor inhibitor and antineoplastic agent that is used in the therapy of selected forms of advanced non-small cell lung cancer (NSCLC) Zykadia is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. Ceritinib is approved to treat Non-small cell lung cancer that is ALK-positive and has metastasized (spread to other parts of the body). It is used in adults. Refractory, locally advanced Nonsmall cell lung cancer Refractory, metastatic Non-small cell lung cancer Use in Cancer Ceritinib is approved to treat: Non-small cell lung cancer that is ALK-positive and has metastasized (spread to other parts of the body). It is used in adults. Ceritinib is also being studied in the treatment of other types of cancer. Contraindications low amount of magnesium in the blood low amount of calcium in the blood low amount of potassium in the blood slow heartbeat prolonged QT interval on EKG chronic heart failure abnormal EKG with QT changes from birth high amount of bilirubin in the blood excessive nausea excessive vomiting excessive diarrhea high blood sugar abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding lung tissue problem pancreatitis Dosage Strengths: 150 mg Non-Small Cell Lung Cancer 450 mg orally once daily at the same time each day until disease progression or unacceptable toxicity Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Dose Adjustments DOSE MODIFICATIONS: First dose reduction: 300 mg once a day Second dose reduction: 150 mg once a day Discontinue this drug in patients unable to tolerate 150 mg daily. DOSE MODIFICATIONS FOR ADVERSE REACTIONS: GI ADVERSE REACTIONS: Severe or intolerable nausea, vomiting, or diarrhea despite antiemetic or antidiarrheal therapy: Withhold therapy until improved; resume at the next lower dose. HEPATOTOXICITY: ALT or AST elevation greater than 5 times the upper limit of normal (ULN) with total bilirubin elevation less than or equal to 2 x ULN: Withhold therapy until recovery to baseline or less than or equal to 3 x ULN; resume at the next lower dose. ALT or AST elevation greater than 3 x ULN with total bilirubin elevation greater than 2 x ULN in the absence of cholestasis or hemolysis: Permanently discontinue therapy. INTERSTITIAL LUNG DISEASE (ILD)/PNEUMONITIS: Any Grade therapy-related ILD/pneumonitis: Permanently discontinue therapy. QT INTERVAL PROLONGATION: QTc interval greater than 500 msec on at least 2 separate ECGs: Withhold therapy until QTc interval is less than 481 msec or recovery to baseline if baseline QTc is greater than or equal to 481 msec; resume at the next lower dose. QTc interval prolongation in combination with Torsades de pointes or polymorphic ventricular tachycardia or serious arrhythmia: Permanently discontinue therapy. HYPERGLYCEMIA: Persistent hyperglycemia greater than 250 mg/dL despite antihyperglycemic therapy: Withhold therapy until hyperglycemia is adequately controlled; resume at the next lower dose; if adequate hyperglycemic control cannot be achieved with medical management, discontinue this drug. BRADYCARDIA: Symptomatic bradycardia that is not life-threatening: Withhold therapy until recovery to asymptomatic bradycardia or to the heart rate of 60 bpm or above, evaluate concomitant medications known to cause bradycardia; if bradycardia cannot be attributed to another drug, resume therapy at the next lower dose. Clinically significant bradycardia requiring intervention or life-threatening bradycardia in patients taking a concomitant medication also known to cause bradycardia or a medication known to cause hypotension: Permanently discontinue therapy. PANCREATITIS: Lipase or amylase elevation greater than 2 x ULN: Withhold therapy until recovery to less than 1.5 x ULN; resume at the next lower dose. STRONG CYP450 3A INHIBITORS (e.g. ketoconazole): Avoid use if possible. If users cannot be avoided, reduce the dose of ceritinib by approximately one-third rounded to the nearest multiple of 150 mg. After discontinuation of a strong CYP450 3A inhibitor, resume the ceritinib dose that was taken prior to initiating the strong CYP450 3A inhibitor. Administration Advice: This drug should be taken with food. Do not consume grapefruit or grapefruit juice because they inhibit CYP450 3A. If a dose is missed, make it up unless it is 12 hours or less until the next dose. Discontinue in patients unable to tolerate 300 mg a day. Side Effects The Most Common nausea diarrhea vomiting constipation stomach pain heartburn difficulty swallowing loss of appetite weight loss fatigue rash itching changes in vision muscle, bone, back arm, or leg pain headache pain in the right upper part of the stomach unusual bruising or bleeding dark urine yellowing of the skin and eyes decreased appetite flu-like symptoms itching shortness of breath fever, chills, sore throat, ongoing cough and congestion, or other signs of infection chest pain or discomfort changes in heartbeat heart palpitations dizziness lightheadedness fainting ongoing pain that begins in the upper left or middle of the stomach but may spread to the back seizures More Common severe pain in your upper stomach spreading to your back; slow heartbeats, weak pulse, weak or shallow breathing; sudden chest pain or discomfort, fever, dry cough or cough with mucus, feeling short of breath; fast or pounding heartbeats, fluttering in your chest, shortness of breath, and sudden dizziness (like you might pass out); high blood sugar–increased thirst, increased urination, hunger, fruity breath odor, headaches, thinking problems, blurred vision, feeling tired; or high blood sugar–increased thirst, increased urination, dry mouth, fruity breath odor; liver problems–right-sided-stomach pain, loss of appetite, unusual tiredness, itching, easy bruising or bleeding, dark urine, or yellowing of the skin or eyes. stomach pain, loss of appetite; nausea, vomiting, diarrhea; feeling tired; or weight loss. Rare Diarrhea Increased gamma-glutamyl transpeptidase (GGT) Increased alkaline phosphatase Increased creatinine Nausea Vomiting Anemia High blood sugar (hyperglycemia) Fatigue Abdominal pain Increased amylase Decreased phosphate Decreased appetite Low white blood cell count (neutropenia) Cough Weight loss Constipation Non-cardiac chest pain Rash Back pain Fever Headache Low platelet count (thrombocytopenia) Esophageal disorder Increased total bilirubin Dizziness Prolonged QT interval Musculoskeletal pain Itching Drug Interaction DRUG INTERACTION Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Ceritinib. Abametapir The serum concentration of Ceritinib can be increased when it is combined with Abametapir. Abatacept The metabolism of Ceritinib can be increased when combined with Abatacept. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Ceritinib. Abrocitinib The serum concentration of Ceritinib can be increased when it is combined with Abrocitinib. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Ceritinib. Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Ceritinib. Acebutolol Acebutolol may increase the bradycardic activities of Ceritinib. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Ceritinib. Acetaminophen The metabolism of Ceritinib can be increased when combined with Acetaminophen. Acetazolamide The metabolism of Ceritinib can be decreased when combined with Acetazolamide. Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ceritinib. Acetylsalicylic acid The metabolism of Acetylsalicylic acid can be decreased when combined with Ceritinib. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Ceritinib. Adalimumab The metabolism of Ceritinib can be increased when combined with Adalimumab. Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Ceritinib. Afatinib The serum concentration of Ceritinib can be increased when it is combined with Afatinib. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Ceritinib. Albendazole The metabolism of Ceritinib can be decreased when combined with Albendazole. Albiglutide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Ceritinib. Aldesleukin The metabolism of Ceritinib can be decreased when combined with Aldesleukin. Alectinib The metabolism of Alectinib can be decreased when combined with Ceritinib. Alfentanil Alfentanil may increase the bradycardic activities of Ceritinib. Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Ceritinib. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Ceritinib. Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Ceritinib. Alosetron The metabolism of Alosetron can be decreased when combined with Ceritinib. Alpelisib The metabolism of Ceritinib can be increased when combined with Alpelisib. Alprazolam The metabolism of Alprazolam can be decreased when combined with Ceritinib. Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ceritinib. Ambrisentan The serum concentration of Ceritinib can be increased when it is combined with Ambrisentan. Amifampridine The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Amifampridine. Aminoglutethimide The metabolism of Ceritinib can be increased when combined with Aminoglutethimide. Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Ceritinib. Aminophylline The metabolism of Aminophylline can be decreased when combined with Ceritinib. Amiodarone Amiodarone may increase the bradycardic activities of Ceritinib. Amisulpride The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Amisulpride. Amitriptyline The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Ceritinib. Amlodipine Amlodipine may increase the bradycardic activities of Ceritinib. Amobarbital The metabolism of Ceritinib can be increased when combined with Amobarbital. Amodiaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Ceritinib. Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Ceritinib. Amprenavir The metabolism of Ceritinib can be decreased when combined with Amprenavir. Anagrelide The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Anagrelide. Anakinra The metabolism of Ceritinib can be increased when combined with Anakinra. Antazoline The risk or severity of QTc prolongation can be increased when Antazoline is combined with Ceritinib. Antipyrine The metabolism of Antipyrine can be decreased when combined with Ceritinib. Apalutamide The serum concentration of Ceritinib can be decreased when it is combined with Apalutamide. Apixaban The metabolism of Apixaban can be decreased when combined with Ceritinib. Apomorphine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ceritinib. Apremilast The metabolism of Ceritinib can be increased when combined with Apremilast. Aprepitant The metabolism of Ceritinib can be decreased when combined with Aprepitant. Arformoterol The metabolism of Arformoterol can be decreased when combined with Ceritinib. Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Ceritinib. Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be decreased when combined with Ceritinib. Armodafinil The metabolism of Ceritinib can be increased when combined with Armodafinil. Arsenic trioxide The serum concentration of Ceritinib can be increased when it is combined with Arsenic trioxide. Artemether The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Artemether. Articaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Articaine. Asciminib The serum concentration of Ceritinib can be increased when it is combined with Asciminib. Asenapine The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Asenapine. Astemizole The metabolism of Astemizole can be decreased when combined with Ceritinib. Asunaprevir The serum concentration of Ceritinib can be increased when it is combined with Asunaprevir. Atazanavir The metabolism of Ceritinib can be decreased when combined with Atazanavir. Atenolol Atenolol may increase the bradycardic activities of Ceritinib. Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ceritinib. Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Ceritinib. Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Ceritinib. Avacopan The metabolism of Ceritinib can be decreased when combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Ceritinib. Avapritinib The metabolism of Avapritinib can be decreased when combined with Ceritinib. Avatrombopag The serum concentration of Ceritinib can be increased when it is combined with Avatrombopag. Axitinib The metabolism of Axitinib can be decreased when combined with Ceritinib. Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Ceritinib. Azelastine The metabolism of Azelastine can be decreased when combined with Ceritinib. Azithromycin The metabolism of Ceritinib can be decreased when combined with Azithromycin. Beclomethasone The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Ceritinib. Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Ceritinib. Belantamab mafodotin The serum concentration of Ceritinib can be increased when it is combined with Belantamab mafodotin. Belinostat The serum concentration of Ceritinib can be increased when it is combined with Belinostat. Belumosudil The serum concentration of Ceritinib can be increased when it is combined with Belumosudil. Belzutifan The serum concentration of Ceritinib can be decreased when it is combined with Belzutifan. Bendamustine The serum concentration of Bendamustine can be increased when it is combined with Ceritinib. Bendroflumethiazide Bendroflumethiazide may increase the bradycardic activities of Ceritinib. Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Ceritinib. Benzocaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Benzyl alcohol. Bepridil Bepridil may increase the bradycardic activities of Ceritinib. Beractant Beractant may increase the bradycardic activities of Ceritinib. Berotralstat The serum concentration of Ceritinib can be increased when it is combined with Berotralstat. Betamethasone The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Ceritinib. Betamethasone The risk or severity of hyperglycemia can be increased when Betamethasone phosphate is combined with Ceritinib. Betaxolol Betaxolol may increase the bradycardic activities of Ceritinib. Betrixaban The serum concentration of Ceritinib can be increased when it is combined with Betrixaban. Bexarotene The metabolism of Ceritinib can be increased when combined with Bexarotene. Bicalutamide The metabolism of Ceritinib can be decreased when combined with Bicalutamide. Bifonazole The metabolism of Ceritinib can be decreased when combined with Bifonazole. Bilastine The risk or severity of QTc prolongation can be increased when Bilastine is combined with Ceritinib. Bimekizumab The metabolism of Ceritinib can be increased when combined with Bimekizumab. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Ceritinib. Bisoprolol Bisoprolol may increase the bradycardic activities of Ceritinib. Boceprevir The metabolism of Ceritinib can be decreased when combined with Boceprevir. Bortezomib The metabolism of Bortezomib can be decreased when combined with Ceritinib. Bosentan The metabolism of Ceritinib can be increased when combined with Bosentan. Bosutinib The metabolism of Bosutinib can be decreased when combined with Ceritinib. Brentuximab vedotin The metabolism of Brentuximab vedotin can be decreased when combined with Ceritinib. Bretylium Bretylium may increase the bradycardic activities of Ceritinib. Brigatinib The metabolism of Brigatinib can be decreased when combined with Ceritinib. Brivaracetam The metabolism of Brivaracetam can be decreased when combined with Ceritinib. Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Ceritinib. Brompheniramine The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Ceritinib. Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Ceritinib. Budesonide The risk or severity of hyperglycemia can be increased when Budesonide is combined with Ceritinib. Bupivacaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Bupivacaine. Buprenorphine The metabolism of Ceritinib can be decreased when combined with Buprenorphine. Bupropion The metabolism of Bupropion can be decreased when combined with Ceritinib. Buserelin The risk or severity of QTc prolongation can be increased when Buserelin is combined with Ceritinib. Busulfan The metabolism of Busulfan can be decreased when combined with Ceritinib. Butacaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Butacaine. Butalbital The metabolism of Ceritinib can be increased when combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Butamben. Butriptyline The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Ceritinib. Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Ceritinib. Cabergoline The metabolism of Cabergoline can be decreased when combined with Ceritinib. Cabozantinib The metabolism of Cabozantinib can be decreased when combined with Ceritinib. Calcitriol The metabolism of Ceritinib can be increased when combined with Calcitriol. Calfactant Calfactant may increase the bradycardic activities of Ceritinib. Canagliflozin The serum concentration of Ceritinib can be increased when it is combined with Canagliflozin. Canakinumab The metabolism of Ceritinib can be increased when combined with Canakinumab. Candesartan cilexetil The metabolism of Candesartan cilexetil can be decreased when combined with Ceritinib. Candicidin The metabolism of Ceritinib can be decreased when combined with Candicidin. Cannabidiol The metabolism of Ceritinib can be decreased when combined with Cannabidiol. Capecitabine The metabolism of Capecitabine can be decreased when combined with Ceritinib. Capmatinib The serum concentration of Ceritinib can be increased when it is combined with Capmatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Capsaicin. Carbamazepine The metabolism of Ceritinib can be increased when combined with Carbamazepine. Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Ceritinib. Carbinoxamine The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Ceritinib. Carfilzomib The serum concentration of Ceritinib can be increased when it is combined with Carfilzomib. Carvedilol Carvedilol may increase the bradycardic activities of Ceritinib. Cefradine The metabolism of Ceritinib can be increased when combined with Cefradine. Celecoxib The metabolism of Celecoxib can be decreased when combined with Ceritinib. Celiprolol Celiprolol may increase the bradycardic activities of Ceritinib. Cenobamate The serum concentration of Ceritinib can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Ceritinib can be decreased when combined with Cephalexin. Cerivastatin The metabolism of Ceritinib can be increased when combined with Cerivastatin. Certolizumab pegol The metabolism of Ceritinib can be increased when combined with Certolizumab pegol. Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Ceritinib. Chloramphenicol The metabolism of Ceritinib can be decreased when combined with Chloramphenicol. Chlorcyclizine The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Ceritinib. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Chloroprocaine. Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Ceritinib. Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Ceritinib. Chlorpromazine The metabolism of Ceritinib can be increased when combined with Chlorpromazine. Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ceritinib. Chlorprothixene The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Ceritinib. Ciclesonide The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Ceritinib. Cilostazol The metabolism of Cilostazol can be decreased when combined with Ceritinib. Cimetidine The metabolism of Ceritinib can be decreased when combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Cinchocaine. Cinnarizine Cinnarizine may increase the bradycardic activities of Ceritinib. Cinoxacin The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Ceritinib. Ciprofloxacin The metabolism of Ceritinib can be decreased when combined with Ciprofloxacin. Cisapride The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Cisapride. Citalopram The metabolism of Ceritinib can be decreased when combined with Citalopram. Clarithromycin The metabolism of Ceritinib can be decreased when combined with Clarithromycin. Clemastine The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Clemastine. Clevidipine Clevidipine may increase the bradycardic activities of Ceritinib. Clobazam The metabolism of Ceritinib can be increased when combined with Clobazam. Clobetasol The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Ceritinib. Clofazimine The serum concentration of Ceritinib can be increased when it is combined with Clofazimine. Clofibrate The metabolism of Ceritinib can be increased when combined with Clofibrate. Clomifene The serum concentration of Ceritinib can be increased when it is combined with Clomifene. Clomipramine The metabolism of Clomipramine can be decreased when combined with Ceritinib. Clonidine Clonidine may increase the bradycardic activities of Ceritinib. Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Ceritinib. Clozapine The metabolism of Ceritinib can be increased when combined with Clozapine. Cobicistat The metabolism of Ceritinib can be decreased when combined with Cobicistat. Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Ceritinib. Cocaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Cocaine. Colchicine The metabolism of Colchicine can be decreased when combined with Ceritinib. Conivaptan The metabolism of Ceritinib can be decreased when combined with Conivaptan. Copanlisib The metabolism of Copanlisib can be decreased when combined with Ceritinib. Corticotropin The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Ceritinib. Cortisone acetate The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Ceritinib. Crizotinib Crizotinib may increase the bradycardic activities of Ceritinib. Curcumin The metabolism of Ceritinib can be decreased when combined with Curcumin. Cyclandelate Cyclandelate may increase the bradycardic activities of Ceritinib. Cyclizine The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Ceritinib. Cyclophosphamide The metabolism of Ceritinib can be increased when combined with Cyclophosphamide. Cyclosporine The serum concentration of Ceritinib can be increased when it is combined with Cyclosporine. Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Ceritinib. Cyproterone acetate The metabolism of Ceritinib can be decreased when combined with Cyproterone acetate. Dabigatran etexilate The serum concentration of Ceritinib can be increased when it is combined with Dabigatran etexilate. Dabrafenib The serum concentration of Ceritinib can be decreased when it is combined with Dabrafenib. Daclatasvir The serum concentration of Ceritinib can be increased when it is combined with Daclatasvir. Dacomitinib The serum concentration of Ceritinib can be increased when it is combined with Dacomitinib. Dactinomycin The serum concentration of Ceritinib can be increased when it is combined with Dactinomycin. Dalfopristin The metabolism of Ceritinib can be decreased when combined with Dalfopristin. Danazol The metabolism of Ceritinib can be decreased when combined with Danazol. You Might Also Read Rasburicase - Uses, Dosage, Side Effects, Interaction Dapagliflozin The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ceritinib. Dapsone The metabolism of Dapsone can be decreased when combined with Ceritinib. Daptomycin The serum concentration of Ceritinib can be increased when it is combined with Daptomycin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ceritinib. Darolutamide The serum concentration of Ceritinib can be increased when it is combined with Darolutamide. Darunavir The serum concentration of Ceritinib can be increased when it is combined with Darunavir. Dasabuvir The serum concentration of Ceritinib can be increased when it is combined with Dasabuvir. Dasatinib The metabolism of Ceritinib can be decreased when combined with Dasatinib. Daunorubicin The metabolism of Ceritinib can be decreased when combined with Daunorubicin. Deferasirox The metabolism of Ceritinib can be increased when combined with Deferasirox. Deflazacort The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Ceritinib. Degarelix The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ceritinib. Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Ceritinib. Delamanid Ceritinib may increase the QTc-prolonging activities of Delamanid. Delavirdine The metabolism of Ceritinib can be decreased when combined with Delavirdine. Desflurane The risk or severity of QTc prolongation can be increased when Desflurane is combined with Ceritinib. Desipramine The metabolism of Ceritinib can be decreased when combined with Desipramine. Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Ceritinib. Desogestrel The metabolism of Desogestrel can be decreased when combined with Ceritinib. Desoximetasone The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Ceritinib. Desvenlafaxine The metabolism of Ceritinib can be decreased when combined with Desvenlafaxine. Deutetrabenazine The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Deutetrabenazine. Dexamethasone The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Ceritinib. Dexamethasone acetate The risk or severity of hyperglycemia can be increased when Dexamethasone acetate is combined with Ceritinib. Dexbrompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ceritinib. Dexchlorpheniramine The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Dexchlorpheniramine maleate. Dexibuprofen The metabolism of Dexibuprofen can be decreased when combined with Ceritinib. Dexmedetomidine Dexmedetomidine may increase the bradycardic activities of Ceritinib. Dextromethorphan The metabolism of Dextromethorphan can be decreased when combined with Ceritinib. Dextropropoxyphene The metabolism of Ceritinib can be decreased when combined with Dextropropoxyphene. Diazepam The metabolism of Diazepam can be decreased when combined with Ceritinib. Diclofenac The metabolism of Diclofenac can be decreased when combined with Ceritinib. Dicloxacillin The metabolism of Ceritinib can be increased when combined with Dicloxacillin. Dicoumarol The metabolism of Dicoumarol can be decreased when combined with Ceritinib. Diethylstilbestrol The metabolism of Ceritinib can be decreased when combined with Diethylstilbestrol. Difluocortolone The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Ceritinib. Digitoxin The metabolism of Digitoxin can be decreased when combined with Ceritinib. Digoxin Digoxin may increase the bradycardic activities of Ceritinib. Dihydroergocornine The metabolism of Ceritinib can be decreased when combined with Dihydroergocornine. Dihydroergocristine The metabolism of Ceritinib can be decreased when combined with Dihydroergocristine. Dihydroergotamine The metabolism of Dihydroergotamine can be decreased when combined with Ceritinib. Diltiazem Diltiazem may increase the bradycardic activities of Ceritinib. Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Ceritinib. Dimethyl sulfoxide The metabolism of Ceritinib can be decreased when combined with Dimethyl sulfoxide. Diosmin The serum concentration of Ceritinib can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Diphenhydramine. Disopyramide The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Disopyramide. Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Ceritinib. Docetaxel The metabolism of Docetaxel can be decreased when combined with Ceritinib. Doconexent The metabolism of Doconexent can be decreased when combined with Ceritinib. Dofetilide The metabolism of Dofetilide can be decreased when combined with Ceritinib. Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Ceritinib. Dolutegravir The serum concentration of Ceritinib can be increased when it is combined with Dolutegravir. Domperidone The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Domperidone. Donepezil Donepezil may increase the bradycardic activities of Ceritinib. Dosulepin The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Ceritinib. Doxazosin The metabolism of Ceritinib can be decreased when combined with Doxazosin. Doxepin The metabolism of Doxepin can be decreased when combined with Ceritinib. Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Ceritinib. Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ceritinib. Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Ceritinib. Dronedarone Dronedarone may increase the bradycardic activities of Ceritinib. Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Ceritinib. Drospirenone The metabolism of Ceritinib can be decreased when combined with Drospirenone. Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ceritinib. Duloxetine The metabolism of Duloxetine can be decreased when combined with Ceritinib. Duvelisib The metabolism of Ceritinib can be decreased when combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Dyclonine. Ebastine The metabolism of Ceritinib can be decreased when combined with Ebastine. Echinacea The metabolism of Ceritinib can be increased when combined with Echinacea. Edoxaban The serum concentration of Ceritinib can be increased when it is combined with Edoxaban. Efavirenz The metabolism of Ceritinib can be decreased when combined with Efavirenz. Elagolix The serum concentration of Ceritinib can be increased when it is combined with Elagolix. Elbasvir The serum concentration of Ceritinib can be increased when it is combined with Elbasvir. Eletriptan The metabolism of Eletriptan can be decreased when combined with Ceritinib. Elexacaftor The metabolism of Ceritinib can be decreased when combined with Elexacaftor. Eliglustat The metabolism of Eliglustat can be decreased when combined with Ceritinib. Elvitegravir The metabolism of Ceritinib can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Ceritinib can be increased when combined with Emapalumab. Emedastine The risk or severity of QTc prolongation can be increased when Emedastine is combined with Ceritinib. Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ceritinib. Enasidenib The serum concentration of Ceritinib can be increased when it is combined with Enasidenib. Encainide The risk or severity of QTc prolongation can be increased when Encainide is combined with Ceritinib. Encorafenib The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Encorafenib. Enfortumab vedotin The serum concentration of Ceritinib can be increased when it is combined with Enfortumab vedotin. Enoxacin The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Ceritinib. Entrectinib The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Entrectinib. Enzalutamide The serum concentration of Ceritinib can be decreased when it is combined with Enzalutamide. Epinastine The risk or severity of QTc prolongation can be increased when Epinastine is combined with Ceritinib. Epinephrine The metabolism of Ceritinib can be decreased when combined with Epinephrine. Erdafitinib The serum concentration of Ceritinib can be increased when it is combined with Erdafitinib. Ergotamine The metabolism of Ceritinib can be decreased when combined with Ergotamine. Eribulin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ceritinib. Erlotinib The metabolism of Erlotinib can be decreased when combined with Ceritinib. Ertugliflozin The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Ceritinib. Erythromycin The serum concentration of Ceritinib can be increased when it is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ceritinib. Escitalopram The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Escitalopram. Esketamine The metabolism of Ceritinib can be increased when combined with Esketamine. Eslicarbazepine The metabolism of Ceritinib can be increased when combined with Eslicarbazepine. Esmolol Esmolol may increase the bradycardic activities of Ceritinib. Estetrol The metabolism of Ceritinib can be decreased when combined with Estetrol. Estradiol The metabolism of Estradiol can be decreased when combined with Ceritinib. Estradiol acetate The metabolism of Ceritinib can be increased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Ceritinib can be increased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Ceritinib can be increased when combined with Estradiol cypionate. Estradiol The metabolism of Ceritinib can be increased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Ceritinib can be increased when combined with Estradiol valerate. Estrone sulfate The metabolism of Estrone sulfate can be decreased when combined with Ceritinib. Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Ceritinib. Etanercept The metabolism of Ceritinib can be increased when combined with Etanercept. Ethambutol The metabolism of Ceritinib can be decreased when combined with Ethambutol. Ethanol The metabolism of Ceritinib can be increased when combined with Ethanol. Ethinylestradiol The metabolism of Ethinylestradiol can be decreased when combined with Ceritinib. Ethosuximide Ethosuximide may increase the bradycardic activities of Ceritinib. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Etidocaine. Etodolac The metabolism of Etodolac can be decreased when combined with Ceritinib. Etoposide The metabolism of Etoposide can be decreased when combined with Ceritinib. Etoricoxib The metabolism of Ceritinib can be decreased when combined with Etoricoxib. Etravirine The metabolism of Ceritinib can be increased when combined with Etravirine. Everolimus The serum concentration of Ceritinib can be increased when it is combined with Everolimus. Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Ceritinib. Ezogabine The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Ceritinib. Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ceritinib. Favipiravir The serum concentration of Ceritinib can be increased when it is combined with Favipiravir. Fedratinib The serum concentration of Ceritinib can be increased when it is combined with Fedratinib. Felbamate The metabolism of Ceritinib can be increased when combined with Felbamate. Felodipine Felodipine may increase the bradycardic activities of Ceritinib. Fenofibrate The metabolism of Ceritinib can be decreased when combined with Fenofibrate. Fentanyl The metabolism of Fentanyl can be decreased when combined with Ceritinib. Fexinidazole The risk or severity of adverse effects can be increased when Ceritinib is combined with Fexinidazole. Fexofenadine The serum concentration of Ceritinib can be increased when it is combined with Fexofenadine. Filgotinib The serum concentration of Ceritinib can be increased when it is combined with Filgotinib. Finerenone The serum concentration of Finerenone can be increased when it is combined with Ceritinib. Fingolimod Fingolimod may increase the bradycardic activities of Ceritinib. Flecainide The risk or severity of QTc prolongation can be increased when Flecainide is combined with Ceritinib. Flibanserin The serum concentration of Ceritinib can be increased when it is combined with Flibanserin. Flucloxacillin The metabolism of Ceritinib can be increased when combined with Flucloxacillin. Fluconazole The serum concentration of Ceritinib can be increased when it is combined with Fluconazole. Fludrocortisone The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Ceritinib. Fluindione The metabolism of Fluindione can be decreased when combined with Ceritinib. Flumethasone The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Ceritinib. Flunarizine Flunarizine may increase the bradycardic activities of Ceritinib. Flunisolide The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Ceritinib. Flunitrazepam The metabolism of Flunitrazepam can be decreased when combined with Ceritinib. Fluocinolone The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Ceritinib. Fluocinonide The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Ceritinib. Fluocortolone The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Ceritinib. Fluorometholone The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Ceritinib. Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ceritinib. Fluoxetine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ceritinib. Flupentixol The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Flupentixol. Fluprednisolone The risk or severity of hyperglycemia can be increased when Fluprednisolone is combined with Ceritinib. Flurbiprofen The metabolism of Flurbiprofen can be decreased when combined with Ceritinib. Fluspirilene Fluspirilene may increase the bradycardic activities of Ceritinib. Fluticasone The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Ceritinib. Fluticasone furoate The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Ceritinib. Fluticasone The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Ceritinib. Fluvastatin The metabolism of Fluvastatin can be decreased when combined with Ceritinib. Fluvoxamine The metabolism of Ceritinib can be decreased when combined with Fluvoxamine. Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Ceritinib. Formestane The metabolism of Ceritinib can be increased when combined with Formestane. Formoterol The metabolism of Formoterol can be decreased when combined with Ceritinib. Fosamprenavir The metabolism of Ceritinib can be decreased when combined with Fosamprenavir. Fosaprepitant The metabolism of Ceritinib can be increased when combined with Fosaprepitant. Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Ceritinib. Fosnetupitant The metabolism of Ceritinib can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Ceritinib can be increased when combined with Fosphenytoin. Fostamatinib The metabolism of Ceritinib can be decreased when combined with Fostamatinib. Fostemsavir The serum concentration of Ceritinib can be increased when it is combined with Fostemsavir. Fusidic acid The metabolism of Ceritinib can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Ceritinib can be increased when it is combined with Futibatinib. Gadobenic acid The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Ceritinib. Galantamine Galantamine may increase the bradycardic activities of Ceritinib. Gatifloxacin The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Ceritinib. Gemcitabine The serum concentration of Ceritinib can be increased when it is combined with Gemcitabine. Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Ceritinib. Gilteritinib The metabolism of Ceritinib can be decreased when combined with Gilteritinib. Ginkgo biloba The metabolism of Ceritinib can be decreased when combined with Ginkgo biloba. Glasdegib The serum concentration of Ceritinib can be increased when it is combined with Glasdegib. Glecaprevir The serum concentration of Ceritinib can be increased when it is combined with Glecaprevir. Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Ceritinib. Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ceritinib. Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Ceritinib. Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Ceritinib. Glyburide The metabolism of Ceritinib can be decreased when combined with Glyburide. Glycerol The metabolism of Ceritinib can be increased when combined with Glycerol phenylbutyrate. Glymidine The therapeutic efficacy of Glymidine can be decreased when used in combination with Ceritinib. Golimumab The metabolism of Ceritinib can be increased when combined with Golimumab. Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ceritinib. Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Ceritinib. Grazoprevir The serum concentration of Ceritinib can be increased when it is combined with Grazoprevir. Grepafloxacin The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Grepafloxacin. Griseofulvin The metabolism of Ceritinib can be increased when combined with Griseofulvin. Guanfacine Guanfacine may increase the bradycardic activities of Ceritinib. Halofantrine The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Halofantrine. Haloperidol The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Haloperidol. Halothane The metabolism of Halothane can be decreased when combined with Ceritinib. You Might Also Read Clonidine; Indications/Uses, Dosage, Side Effects, Interaction ,Pregnancy Hydralazine The metabolism of Ceritinib can be decreased when combined with Hydralazine. Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Ceritinib. Hydrocortamate The metabolism of Ceritinib can be increased when combined with Hydrocortamate. Hydrocortisone The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Ceritinib. Hydrocortisone acetate The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Ceritinib. Hydrocortisone butyrate The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Ceritinib. Hydrocortisone The risk or severity of hyperglycemia can be increased when Hydrocortisone cypionate is combined with Ceritinib. Hydrocortisone The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Ceritinib. Hydromorphone The metabolism of Hydromorphone can be decreased when combined with Ceritinib. Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Ceritinib. Hydroxyzine The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Hydroxyzine. Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ceritinib. Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ceritinib. Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Ceritinib. Ibuprofen The metabolism of Ibuprofen can be decreased when combined with Ceritinib. Ibutilide The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Ibutilide. Idarubicin The metabolism of Idarubicin can be decreased when combined with Ceritinib. Idelalisib The metabolism of Idelalisib can be decreased when combined with Ceritinib. Ifosfamide The metabolism of Ceritinib can be increased when combined with Ifosfamide. Iloperidone The metabolism of Iloperidone can be decreased when combined with Ceritinib. Imatinib The serum concentration of Ceritinib can be increased when it is combined with Imatinib. Imipramine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Ceritinib. Indacaterol The serum concentration of Ceritinib can be increased when it is combined with Indacaterol. Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Ceritinib. Indinavir The metabolism of Ceritinib can be decreased when combined with Indinavir. Indomethacin The metabolism of Indomethacin can be decreased when combined with Ceritinib. Infigratinib The metabolism of Ceritinib can be decreased when combined with Infigratinib. Infliximab The metabolism of Ceritinib can be increased when combined with Infliximab. Inotersen The risk or severity of QTc prolongation can be increased when Inotersen is combined with Ceritinib. Inotuzumab The serum concentration of Ceritinib can be increased when it is combined with Inotuzumab ozogamicin. Insulin aspart The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Ceritinib. Insulin beef The therapeutic efficacy of Insulin beef can be decreased when used in combination with Ceritinib. Insulin degludec The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Ceritinib. Insulin detemir The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Ceritinib. Insulin glargine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Ceritinib. Insulin glulisine The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Ceritinib. Insulin human The therapeutic efficacy of Insulin human can be decreased when used in combination with Ceritinib. Insulin lispro The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Ceritinib. Insulin pork The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ceritinib. Irbesartan The metabolism of Ceritinib can be decreased when combined with Irbesartan. Irinotecan The metabolism of Irinotecan can be decreased when combined with Ceritinib. Isavuconazole The serum concentration of Ceritinib can be increased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Ceritinib can be increased when it is combined with Isavuconazonium. Isoflurane The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Ceritinib. Isoniazid The metabolism of Ceritinib can be decreased when combined with Isoniazid. Isradipine Isradipine may increase the bradycardic activities of Ceritinib. Istradefylline The serum concentration of Ceritinib can be increased when it is combined with Istradefylline. Itraconazole The metabolism of Ceritinib can be decreased when combined with Itraconazole. Ivabradine Ivabradine may increase the bradycardic activities of Ceritinib. Ivacaftor The serum concentration of Ceritinib can be increased when it is combined with Ivacaftor. Ivosidenib The metabolism of Ceritinib can be increased when combined with Ivosidenib. Ixabepilone The serum concentration of Ceritinib can be increased when it is combined with Ixabepilone. Ixazomib The metabolism of Ixazomib can be decreased when combined with Ceritinib. Ketamine The metabolism of Ketamine can be decreased when combined with Ceritinib. Ketazolam The metabolism of Ceritinib can be decreased when combined with Ketazolam. Ketoconazole The metabolism of Ceritinib can be decreased when combined with Ketoconazole. Ketorolac The metabolism of Ketorolac can be decreased when combined with Ceritinib. Labetalol Labetalol may increase the bradycardic activities of Ceritinib. Lacidipine Lacidipine may increase the bradycardic activities of Ceritinib. Lacosamide Lacosamide may increase the bradycardic activities of Ceritinib. Lamotrigine Lamotrigine may increase the bradycardic activities of Ceritinib. Lanreotide Lanreotide may increase the bradycardic activities of Ceritinib. Lansoprazole The metabolism of Lansoprazole can be decreased when combined with Ceritinib. Lapatinib The serum concentration of Ceritinib can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Ceritinib can be increased when it is combined with Larotrectinib. Lasmiditan The serum concentration of Ceritinib can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Ceritinib can be increased when it is combined with Ledipasvir. Lefamulin Lefamulin may increase the QTc-prolonging activities of Ceritinib. Leflunomide The metabolism of Leflunomide can be decreased when combined with Ceritinib. Lemborexant The serum concentration of Ceritinib can be increased when it is combined with Lemborexant. Lenvatinib The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Lenvatinib. Lercanidipine Lercanidipine may increase the bradycardic activities of Ceritinib. Lesinurad The metabolism of Ceritinib can be increased when combined with Lesinurad. Letermovir The metabolism of Ceritinib can be decreased when combined with Letermovir. Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ceritinib. Levacetylmethadol The metabolism of Levacetylmethadol can be decreased when combined with Ceritinib. Levamlodipine The serum concentration of Levamlodipine can be increased when it is combined with Ceritinib. Levobetaxolol Levobetaxolol may increase the bradycardic activities of Ceritinib. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Levobupivacaine. Levocabastine The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Ceritinib. Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Ceritinib. Levofloxacin The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ceritinib. Levoketoconazole The metabolism of Ceritinib can be decreased when combined with Levoketoconazole. Levomenthol Levomenthol may increase the bradycardic activities of Ceritinib. Levosimendan The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Ceritinib. Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Ceritinib. Lidocaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Lidocaine. Lidoflazine Lidoflazine may increase the bradycardic activities of Ceritinib. Linagliptin The serum concentration of Ceritinib can be increased when it is combined with Linagliptin. Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Ceritinib. Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Ceritinib. Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Ceritinib. Lixisenatide The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Ceritinib. Lofexidine The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Ceritinib. Lomefloxacin The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Ceritinib. Lomitapide The metabolism of Lomitapide can be decreased when combined with Ceritinib. Lonafarnib The metabolism of Ceritinib can be decreased when combined with Lonafarnib. Loncastuximab The serum concentration of Ceritinib can be increased when it is combined with Loncastuximab tesirine. Loperamide Loperamide may increase the bradycardic activities of Ceritinib. Nitrendipine Nitrendipine may increase the bradycardic activities of Ceritinib. Norethisterone The metabolism of Ceritinib can be decreased when combined with Norethisterone. Norfloxacin The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Ceritinib. Norgestimate The serum concentration of Ceritinib can be increased when it is combined with Norgestimate. Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Ceritinib. Noscapine The metabolism of Ceritinib can be decreased when combined with Noscapine. Nylidrin Nylidrin may increase the bradycardic activities of Ceritinib. Octreotide Octreotide may increase the bradycardic activities of Ceritinib. Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Ceritinib. Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Ceritinib. Olaparib The metabolism of Olaparib can be decreased when combined with Ceritinib. Olodaterol The metabolism of Olodaterol can be decreased when combined with Ceritinib. Omadacycline The serum concentration of Ceritinib can be increased when it is combined with Omadacycline. Ombitasvir The serum concentration of Ceritinib can be increased when it is combined with Ombitasvir. Omeprazole The metabolism of Ceritinib can be increased when combined with Omeprazole. Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Ceritinib. Oritavancin The metabolism of Ceritinib can be increased when combined with Oritavancin. Orphenadrine The metabolism of Ceritinib can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Ceritinib can be decreased when combined with Osilodrostat. Osimertinib The metabolism of Osimertinib can be decreased when combined with Ceritinib. Ospemifene The metabolism of Ospemifene can be decreased when combined with Ceritinib. Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ceritinib. Oxatomide The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Oxatomide. Oxcarbazepine The metabolism of Ceritinib can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Oxetacaine. Oxprenolol Oxprenolol may increase the bradycardic activities of Ceritinib. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Oxybuprocaine. Oxybutynin The metabolism of Ceritinib can be decreased when combined with Oxybutynin. Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ceritinib. Paclitaxel The metabolism of Ceritinib can be increased when combined with Paclitaxel. Pacritinib The serum concentration of Ceritinib can be increased when it is combined with Pacritinib. Palbociclib The serum concentration of Ceritinib can be increased when it is combined with Palbociclib. Paliperidone The serum concentration of Ceritinib can be increased when it is combined with Paliperidone. Panobinostat The metabolism of Panobinostat can be decreased when combined with Ceritinib. Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ceritinib. Paramethadione The metabolism of Paramethadione can be decreased when combined with Ceritinib. Parathyroid The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ceritinib. Parecoxib The metabolism of Parecoxib can be decreased when combined with Ceritinib. Paritaprevir The serum concentration of Ceritinib can be increased when it is combined with Paritaprevir. Pasireotide Pasireotide may increase the bradycardic activities of Ceritinib. Pazopanib The metabolism of Ceritinib can be decreased when combined with Pazopanib. Pefloxacin The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Ceritinib. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Ceritinib. Penbutolol Penbutolol may increase the bradycardic activities of Ceritinib. Pentamidine The therapeutic efficacy of Pentamidine can be decreased when used in combination with Ceritinib. Pentobarbital The metabolism of Ceritinib can be increased when combined with Pentobarbital. Perampanel The metabolism of Ceritinib can be increased when combined with Perampanel. Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Ceritinib. Perhexiline Perhexiline may increase the bradycardic activities of Ceritinib. Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Ceritinib. Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Ceritinib. Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ceritinib. Phenobarbital The metabolism of Ceritinib can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Phenol. Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Ceritinib. Phenylbutazone The metabolism of Ceritinib can be increased when combined with Phenylbutazone. Phenytoin The metabolism of Ceritinib can be increased when combined with Phenytoin. Pibrentasvir The serum concentration of Ceritinib can be increased when it is combined with Pibrentasvir. Pimavanserin The metabolism of Ceritinib can be decreased when combined with Pimavanserin. Pimozide The metabolism of Pimozide can be decreased when combined with Ceritinib. Pinaverium Pinaverium may increase the bradycardic activities of Ceritinib. Pindolol Pindolol may increase the bradycardic activities of Ceritinib. Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Ceritinib. Piperaquine The metabolism of Ceritinib can be decreased when combined with Piperaquine. Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Ceritinib. Piroxicam The metabolism of Piroxicam can be decreased when combined with Ceritinib. Pitavastatin The metabolism of Pitavastatin can be decreased when combined with Ceritinib. Pitolisant The serum concentration of Ceritinib can be decreased when it is combined with Pitolisant. Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Ceritinib. Ponatinib The serum concentration of Ceritinib can be increased when it is combined with Ponatinib. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Ceritinib. Poractant alfa Poractant alfa may increase the bradycardic activities of Ceritinib. Posaconazole The metabolism of Ceritinib can be decreased when combined with Posaconazole. Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Ceritinib. Potassium The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Ceritinib. Practolol Practolol may increase the bradycardic activities of Ceritinib. Pralsetinib The serum concentration of Ceritinib can be increased when it is combined with Pralsetinib. Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Ceritinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Pramocaine. Prasugrel The metabolism of Prasugrel can be decreased when combined with Ceritinib. Pravastatin The serum concentration of Ceritinib can be increased when it is combined with Pravastatin. Prednisolone The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Ceritinib. Prednisolone acetate The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Ceritinib. Prednisolone The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Ceritinib. Prednisone The risk or severity of hyperglycemia can be increased when Prednisone is combined with Ceritinib. Prednisone acetate The risk or severity of hyperglycemia can be increased when Prednisone acetate is combined with Ceritinib. Pregabalin Pregabalin may increase the bradycardic activities of Ceritinib. Prenylamine Prenylamine may increase the bradycardic activities of Ceritinib. Pretomanid The metabolism of Ceritinib can be decreased when combined with Pretomanid. Prilocaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Prilocaine. Primaquine The metabolism of Ceritinib can be decreased when combined with Primaquine. Primidone The metabolism of Ceritinib can be increased when combined with Primidone. Probenecid The metabolism of Ceritinib can be increased when combined with Probenecid. Probucol The risk or severity of QTc prolongation can be increased when Probucol is combined with Ceritinib. Procainamide The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Procainamide. Procaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Procaine. Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Ceritinib. Progesterone The metabolism of Progesterone can be decreased when combined with Ceritinib. Proguanil The metabolism of Proguanil can be decreased when combined with Ceritinib. Promazine The risk or severity of QTc prolongation can be increased when Promazine is combined with Ceritinib. Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Ceritinib. Propafenone Propafenone may increase the bradycardic activities of Ceritinib. Proparacaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Proparacaine. Propofol The metabolism of Ceritinib can be decreased when combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Propoxycaine. Propranolol Propranolol may increase the bradycardic activities of Ceritinib. Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ceritinib. Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Ceritinib. Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Ceritinib. Prucalopride The metabolism of Prucalopride can be decreased when combined with Ceritinib. Quazepam The metabolism of Quazepam can be decreased when combined with Ceritinib. Quetiapine The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Ceritinib. Quinidine The serum concentration of Ceritinib can be increased when it is combined with Quinidine. Quinine The serum concentration of Ceritinib can be increased when it is combined with Quinine. Quinupristin The metabolism of Ceritinib can be decreased when combined with Quinupristin. Raloxifene The metabolism of Ceritinib can be decreased when combined with Raloxifene. Ramelteon The metabolism of Ramelteon can be decreased when combined with Ceritinib. Ranolazine The serum concentration of Ceritinib can be increased when it is combined with Ranolazine. Regorafenib Regorafenib may increase the bradycardic activities of Ceritinib. Relugolix The serum concentration of Ceritinib can be increased when it is combined with Relugolix. Remdesivir The metabolism of Ceritinib can be decreased when combined with Remdesivir. Remifentanil Remifentanil may increase the bradycardic activities of Ceritinib. Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Ceritinib. Reserpine The serum concentration of Ceritinib can be increased when it is combined with Reserpine. Retapamulin The metabolism of Retapamulin can be decreased when combined with Ceritinib. Revefenacin The serum concentration of Ceritinib can be increased when it is combined with Revefenacin. Ribociclib The metabolism of Ceritinib can be decreased when combined with Ribociclib. Rifabutin The metabolism of Ceritinib can be increased when combined with Rifabutin. Rifampicin The serum concentration of Ceritinib can be decreased when it is combined with Rifampicin. Rifamycin The serum concentration of Ceritinib can be increased when it is combined with Rifamycin. Rifapentine The metabolism of Ceritinib can be increased when combined with Rifapentine. Rilonacept The metabolism of Ceritinib can be increased when combined with Rilonacept. Rilpivirine The metabolism of Ceritinib can be decreased when combined with Rilpivirine. Rimegepant The serum concentration of Ceritinib can be increased when it is combined with Rimegepant. Riociguat The serum concentration of Ceritinib can be increased when it is combined with Riociguat. Ripretinib The serum concentration of Ceritinib can be increased when it is combined with Ripretinib. Risperidone The risk or severity of QTc prolongation can be increased when Risperidone is combined with Ceritinib. Ritonavir The metabolism of Ceritinib can be decreased when combined with Ritonavir. Rivaroxaban The serum concentration of Ceritinib can be increased when it is combined with Rivaroxaban. Rivastigmine Rivastigmine may increase the bradycardic activities of Ceritinib. Rofecoxib The metabolism of Ceritinib can be increased when combined with Rofecoxib. Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Ceritinib. Rolapitant The serum concentration of Ceritinib can be increased when it is combined with Rolapitant. Romidepsin The metabolism of Romidepsin can be decreased when combined with Ceritinib. Ropivacaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Ropivacaine. Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ceritinib. Rosoxacin The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Ceritinib. Rosuvastatin The metabolism of Ceritinib can be decreased when combined with Rosuvastatin. Roxithromycin The metabolism of Ceritinib can be decreased when combined with Roxithromycin. Rucaparib The metabolism of Ceritinib can be decreased when combined with Rucaparib. Rufinamide The metabolism of Ceritinib can be increased when combined with Rufinamide. Rupatadine The metabolism of Rupatadine can be decreased when combined with Ceritinib. Ruxolitinib Ruxolitinib may increase the bradycardic activities of Ceritinib. Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ceritinib. Salicylic acid The metabolism of Salicylic acid can be decreased when combined with Ceritinib. Salmeterol The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ceritinib. Salmon calcitonin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Ceritinib. Sapropterin The serum concentration of Ceritinib can be increased when it is combined with Sapropterin. Saquinavir The metabolism of Ceritinib can be decreased when combined with Saquinavir. Sarecycline The serum concentration of Ceritinib can be increased when it is combined with Sarecycline. Sarilumab The metabolism of Ceritinib can be increased when combined with Sarilumab. Satralizumab The serum concentration of Ceritinib can be decreased when it is combined with Satralizumab. Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Ceritinib. Secobarbital The metabolism of Ceritinib can be increased when combined with Secobarbital. Secukinumab The metabolism of Ceritinib can be increased when combined with Secukinumab. Selegiline The metabolism of Selegiline can be decreased when combined with Ceritinib. Selexipag The serum concentration of Ceritinib can be increased when it is combined with Selexipag. Selumetinib The metabolism of Selumetinib can be decreased when combined with Ceritinib. Semaglutide The therapeutic efficacy of Semaglutide can be decreased when used in combination with Ceritinib. Sertraline The metabolism of Sertraline can be decreased when combined with Ceritinib. Sevoflurane The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Ceritinib. Sildenafil The serum concentration of Ceritinib can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Ceritinib can be increased when it is combined with Silodosin. Siltuximab The metabolism of Ceritinib can be increased when combined with Siltuximab. Simeprevir The serum concentration of Ceritinib can be increased when it is combined with Simeprevir. Simvastatin The serum concentration of Ceritinib can be increased when it is combined with Simvastatin. Siponimod The metabolism of Siponimod can be decreased when combined with Ceritinib. Sirolimus The metabolism of Sirolimus can be decreased when combined with Ceritinib. Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Ceritinib. Sitaxentan The metabolism of Ceritinib can be decreased when combined with Sitaxentan. Sofosbuvir The serum concentration of Ceritinib can be increased when it is combined with Sofosbuvir. Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Ceritinib. Somatostatin The metabolism of Ceritinib can be decreased when combined with Somatostatin. Somatrogon The metabolism of Ceritinib can be increased when combined with Somatrogon. Sonidegib The metabolism of Sonidegib can be decreased when combined with Ceritinib. Sorafenib The serum concentration of Ceritinib can be increased when it is combined with Sorafenib. Sotagliflozin The serum concentration of Ceritinib can be increased when it is combined with Sotagliflozin. Sotalol Sotalol may increase the bradycardic activities of Ceritinib. Sotorasib The serum concentration of Ceritinib can be decreased when it is combined with Sotorasib. Sparfloxacin The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Sparfloxacin. St. John’s Wort The serum concentration of Ceritinib can be decreased when it is combined with St. John’s Wort. Stiripentol The metabolism of Ceritinib can be decreased when combined with Stiripentol. Sufentanil Sufentanil may increase the bradycardic activities of Ceritinib. Sulfadiazine The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Ceritinib. Sulfamethoxazole The metabolism of Ceritinib can be decreased when combined with Sulfamethoxazole. Sulfinpyrazone The metabolism of Ceritinib can be increased when combined with Sulfinpyrazone. Sulfisoxazole The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Ceritinib. Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Ceritinib. Sultopride The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Sultopride. Sunitinib The metabolism of Sunitinib can be decreased when combined with Ceritinib. You Might Also Read Belinostat - Uses, Dosage, Side Effects, Interactions Suvorexant The serum concentration of Ceritinib can be increased when it is combined with Suvorexant. Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Ceritinib. Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Ceritinib. Tamoxifen The serum concentration of Ceritinib can be increased when it is combined with Tamoxifen. Tasimelteon The metabolism of Ceritinib can be decreased when combined with Tasimelteon. Tazemetostat The metabolism of Ceritinib can be decreased when combined with Tazemetostat. Technetium The serum concentration of Ceritinib can be increased when it is combined with Technetium Tc-99m sestamibi. Tecovirimat The metabolism of Ceritinib can be increased when combined with Tecovirimat. Tegaserod The serum concentration of Ceritinib can be increased when it is combined with Tegaserod. Telaprevir The metabolism of Ceritinib can be decreased when combined with Telaprevir. Telavancin The risk or severity of QTc prolongation can be increased when Telavancin is combined with Ceritinib. Telithromycin The metabolism of Ceritinib can be decreased when combined with Telithromycin. Telotristat ethyl The serum concentration of Ceritinib can be decreased when it is combined with Telotristat ethyl. Temsirolimus The serum concentration of Ceritinib can be increased when it is combined with Temsirolimus. Teniposide The metabolism of Teniposide can be decreased when combined with Ceritinib. Tenofovir alafenamide The metabolism of Ceritinib can be decreased when combined with Tenofovir alafenamide. Tenofovir disoproxil The serum concentration of Ceritinib can be increased when it is combined with Tenofovir disoproxil. Tenoxicam The metabolism of Tenoxicam can be decreased when combined with Ceritinib. Tepotinib The serum concentration of Ceritinib can be increased when it is combined with Tepotinib. Terbinafine The metabolism of Ceritinib can be increased when combined with Terbinafine. Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ceritinib. Terfenadine The metabolism of Ceritinib can be decreased when combined with Terfenadine. Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Ceritinib. Terlipressin The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Ceritinib. Testosterone The metabolism of Ceritinib can be increased when combined with Testosterone. Testosterone The metabolism of Testosterone cypionate can be decreased when combined with Ceritinib. Testosterone The metabolism of Testosterone enanthate can be decreased when combined with Ceritinib. Tetrabenazine The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Tetrabenazine. Tetracaine The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Tetracaine. Tetracycline The metabolism of Ceritinib can be decreased when combined with Tetracycline. Tezacaftor The serum concentration of Ceritinib can be increased when it is combined with Tezacaftor. Thalidomide The metabolism of Thalidomide can be decreased when combined with Ceritinib. Theophylline The metabolism of Theophylline can be decreased when combined with Ceritinib. Thiamylal The metabolism of Ceritinib can be increased when combined with Thiamylal. Thioridazine The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Thioridazine. Thiotepa The metabolism of Thiotepa can be decreased when combined with Ceritinib. Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Ceritinib. Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Ceritinib. Thyrotropin alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ceritinib. Ticagrelor The serum concentration of Ceritinib can be increased when it is combined with Ticagrelor. Timolol Timolol may increase the bradycardic activities of Ceritinib. Tipranavir The metabolism of Ceritinib can be decreased when combined with Tipranavir. Tirzepatide The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Ceritinib. Tivozanib The serum concentration of Ceritinib can be increased when it is combined with Tivozanib. Tixocortol The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Ceritinib. Tizanidine Tizanidine may increase the bradycardic activities of Ceritinib. Tocilizumab The metabolism of Ceritinib can be increased when combined with Tocilizumab. Tofacitinib Tofacitinib may increase the bradycardic activities of Ceritinib. Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Ceritinib. Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ceritinib. Tolfenamic acid Tolfenamic acid may increase the bradycardic activities of Ceritinib. Tolterodine The metabolism of Tolterodine can be decreased when combined with Ceritinib. Tolvaptan The metabolism of Tolvaptan can be decreased when combined with Ceritinib. Topiramate The metabolism of Ceritinib can be increased when combined with Topiramate. Topotecan The serum concentration of Topotecan can be increased when it is combined with Ceritinib. Torasemide The metabolism of Torasemide can be decreased when combined with Ceritinib. Toremifene The serum concentration of Ceritinib can be increased when it is combined with Toremifene. Trabectedin The metabolism of Trabectedin can be decreased when combined with Ceritinib. Tramadol The metabolism of Tramadol can be decreased when combined with Ceritinib. Trastuzumab The metabolism of Trastuzumab emtansine can be decreased when combined with Ceritinib. Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ceritinib. Treprostinil The metabolism of Treprostinil can be decreased when combined with Ceritinib. Tretinoin The metabolism of Tretinoin can be decreased when combined with Ceritinib. Triamcinolone The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Ceritinib. Triclabendazole The metabolism of Ceritinib can be decreased when combined with Triclabendazole. Trilaciclib The serum concentration of Ceritinib can be increased when it is combined with Trilaciclib. Trilostane The risk or severity of hyperglycemia can be increased when Trilostane is combined with Ceritinib. Trimebutine Trimebutine may increase the bradycardic activities of Ceritinib. Trimethadione Trimethadione may increase the bradycardic activities of Ceritinib. Trimethoprim The metabolism of Trimethoprim can be decreased when combined with Ceritinib. Trimipramine The metabolism of Trimipramine can be decreased when combined with Ceritinib. Triprolidine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Ceritinib. Triptorelin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ceritinib. Troglitazone The metabolism of Ceritinib can be increased when combined with Troglitazone. Troleandomycin The metabolism of Ceritinib can be decreased when combined with Troleandomycin. Trovafloxacin The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Trovafloxacin. Tucatinib Tucatinib may decrease the excretion rate of Ceritinib which could result in a higher serum level. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Ceritinib. Umbralisib The serum concentration of Ceritinib can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Ceritinib can be increased when it is combined with Umeclidinium. Valdecoxib The metabolism of Valdecoxib can be decreased when combined with Ceritinib. Valproic acid The metabolism of Ceritinib can be decreased when combined with Valproic acid. Valsartan The metabolism of Valsartan can be decreased when combined with Ceritinib. Vandetanib The serum concentration of Ceritinib can be increased when it is combined with Vandetanib. Vardenafil The metabolism of Vardenafil can be decreased when combined with Ceritinib. Velpatasvir The serum concentration of Ceritinib can be increased when it is combined with Velpatasvir. Vemurafenib The serum concentration of Ceritinib can be increased when it is combined with Vemurafenib. Venetoclax The serum concentration of Ceritinib can be increased when it is combined with Venetoclax. Verapamil Verapamil may increase the bradycardic activities of Ceritinib. Vernakalant The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Ceritinib. Vilanterol The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Ceritinib. Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ceritinib. Viloxazine The metabolism of Ceritinib can be decreased when combined with Viloxazine. Vinblastine The metabolism of Ceritinib can be increased when combined with Vinblastine. Vincristine The metabolism of Vincristine can be decreased when combined with Ceritinib. Vindesine The metabolism of Vindesine can be decreased when combined with Ceritinib. Vinflunine The metabolism of Vinflunine can be decreased when combined with Ceritinib. Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Ceritinib. Vismodegib The metabolism of Vismodegib can be decreased when combined with Ceritinib. Vitamin E The metabolism of Ceritinib can be increased when combined with Vitamin E. Pregnancy and Lactation FDA Pregnancy Category D Pregnancy Based on animal studies and its mechanism of action, ceritinib therapy can cause fetal harm when administered to a pregnant woman. The limited data available on the use of ceritinib in pregnant women are insufficient to inform risk. Administration to rats and rabbits during the period of organogenesis at maternal plasma exposures below the recommended human dose caused increases in skeletal anomalies in rats and rabbits. Pregnant women should be advised of the potential risk to the fetus. Females of reproductive potential are advised to use effective contraception during treatment with ceritinib and for 6 months following the completion of therapy. Based on the potential for genotoxicity, males with female partners of reproductive potential are advised to use condoms during treatment with ceritinib and for 3 months following completion of therapy. Lactation No information is available on the clinical use of ceritinib during breastfeeding. Because ceritinib is 97% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during ceritinib therapy and for 2 weeks after the final dose. There are no data regarding the presence of ceritinib or its metabolites in human milk, the effects of ceritinib on breastfed infants, or its effects on milk production. Because of the potential for serious adverse reactions including gastrointestinal toxicity, hepatotoxicity, pneumonitis, bradycardia, and pancreatitis, breastfeeding is not recommended during treatment with ceritinib and for 2 weeks following completion of therapy. How should this medicine be used? Ceritinib comes as a capsule and a tablet to take by mouth. It is usually taken with food once a day. Take ceritinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take ceritinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. If you vomit after taking ceritinib, do not take another dose. Continue your regular dosing schedule. Your doctor may decrease your dose of ceritinib, treat you with other medications, or tell you to stop taking ceritinib for a period of time during your treatment. This will depend on how well the medication works for you and any side effects you may experience. Be sure to tell your doctor how you are feeling during your treatment with ceritinib. What special precautions should I follow? Before taking ceritinib, tell your doctor and pharmacist if you are allergic to ceritinib, any other medications, or any of the ingredients in ceritinib capsules or tablets. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: amiodarone (Nexterone, Pacerone); anagrelide (Agrylin); anticoagulants (‘blood thinners’) such as warfarin (Coumadin, Jantoven); beta blockers such as atenolol (Tenormin), labetalol (Normodyne), metoprolol (Lopressor, Toprol XL), nadolol (Corgard), propranolol (Inderal) and sotalol (Betapace, Sorine, Sotylize); carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Teril); certain medications for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) such as efavirenz (Sustiva, in Atripla), indinavir (Crixivan), nelfinavir (Viracept), nevirapine (Viramune), ritonavir (Norvir, in Kaletra), and saquinavir (Invirase); chloroquine; chlorpromazine; cilostazol; ciprofloxacin (Cipro); citalopram (Celexa); clarithromycin; clonidine (Catapres, Kapvay); corticosteroids; cyclosporine (Gengraf, Neoral, Sandimmune); digoxin (Lanoxin); diltiazem (Cardizem, Dilacor, Tiazac); disopyramide (Norpace); dofetilide (Tikosyn); donepezil (Aricept); dronedarone (Multaq); escitalopram (Lexapro); fentanyl (Abstral, Actiq, Duragesic, Fentora, Subsys); flecainide (Tambocor); fluconazole (Diflucan); haloperidol (Haldol); ibutilide (Corvert); itraconazole (Onmel, Sporanox, Tolsura); ketoconazole; levofloxacin; methadone (Dolophine, Methadose); moxifloxacin (Avelox); nefazodone; ondansetron (Zuplenz, Zofran); pentamidine (Pentam); phenobarbital; phenytoin (Dilantin, Phenytek); pimozide (Orap); pioglitazone (Actos, in Duetact, Oseni); procainamide; quinidine (in Nuedexta); rifabutin (Mycobutin); rifampin (Rifadin, Rimactane, in Rifater); sildenafil (Revatio); sirolimus (Rapamune); tacrolimus (Astagraf, Prograf); thioridazine; vardenafil (Levitra, Staxyn); and verapamil (Calan, Covera, Isoptin, Verelan). Many other medications may interact with ceritinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. tell your doctor what herbal products you are taking, especially St. John’s Wort. tell your doctor if you have or have ever had diabetes or high blood sugar, heart failure, an irregular heartbeat, QT prolongation (an irregular heart rhythm that can lead to fainting, loss of consciousness, seizures, or sudden death), a low level of potassium or magnesium in your blood, pancreatitis (inflammation of the pancreas), or liverdisease. tell your doctor if you are pregnant, or plan to become pregnant. You should not become pregnant while you are taking ceritinib. You will need to have a pregnancy test before you start treatment, and you should use birth control to prevent pregnancy during your treatment and for at least 6 months after your final dose. If you are a male with a female partner who may become pregnant, you should use birth control to prevent pregnancy during you treatment and for at least 3 months after your final dose. Talk to your doctor about birth control methods that will work for you. Ceritinib may harm your unborn baby. If you or your partner become pregnant during your treatment with ceritinib, call your doctor immediately. tell your doctor if you are breastfeeding. You should not breastfeed while you are taking ceritinib and for at least 2 weeks after your final dose. if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking ceritinib. you should know that you may experience hyperglycemia (an increase in your blood sugar) while you are taking this medication. Tell your doctor immediately if you have any of the following symptoms while you are taking ceritinib: extreme thirst, frequent urination, extreme hunger, blurred vision, headache, trouble thinking or concentrating, breath that smells like fruit or tiredness. References https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205755s009lbl.pdf https://www.cancer.gov/about-cancer/treatment/drugs/ceritinib https://pubchem.ncbi.nlm.nih.gov/compound/Ceritinib https://pubchem.ncbi.nlm.nih.gov/compound/Ceritinib-dihydrochloride https://medlineplus.gov/druginfo/meds/a614027.html https://go.drugbank.com/drugs/DB09063 https://www.drugs.com/mtm/ceritinib.html https://www.rxlist.com/consumer_zykadia_ceritinib/drugs-condition.htm https://www.webmd.com/drugs/2/drug-166222/ceritinib-oral/details/list-contraindications ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2403108/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp https://ctdbase.org/detail.go?type=chem&acc=C586847 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads https://www.dgidb.org/drugs/CERITINIB DrugBank https://www.drugbank.ca/legal/terms_of_use Ceritinib https://www.drugbank.ca/drugs/DB09063 IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7397 Guide to Pharmacology Target Classification https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) Ceritinib http://idrblab.net/ttd/data/drug/details/D04LVK CAS Common Chemistry LICENSE The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated. https://creativecommons.org/licenses/by-nc/4.0/ Ceritinib https://commonchemistry.cas.org/detail?cas_rn=1032900-25-6 ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Ceritinib [USAN:INN] https://chem.nlm.nih.gov/chemidplus/sid/1032900256 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Ceritinib https://comptox.epa.gov/dashboard/DTXSID10725373 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]- https://echa.europa.eu/information-on-chemicals 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]- https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/249556 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking CERITINIB https://gsrs.ncats.nih.gov/ginas/app/beta/substances/K418KG2GET ChEBI Ceritinib http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:78432 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking CERITINIB https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Ceritinib https://www.ncbi.nlm.nih.gov/books/n/livertox/Ceritinib/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C115112 NCI Thesaurus Tree https://ncit.nci.nih.gov ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ DailyMed LICENSE https://www.nlm.nih.gov/copyright.html CERITINIB https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=CERITINIB Nature Chemical Biology https://pubchem.ncbi.nlm.nih.gov/substance/342578766 European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice Zykadia (EMEA/H/C/003819) https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia Drugs and Lactation Database (LactMed) LICENSE https://www.nlm.nih.gov/copyright.html Ceritinib https://www.ncbi.nlm.nih.gov/books/NBK500841/ EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book NORMAN Suspect List Exchange LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking CERITINIB https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory Human Metabolome Database (HMDB) http://www.hmdb.ca/citing ceritinib http://www.hmdb.ca/metabolites/HMDB0249821 NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Ceritinib https://www.cancer.gov/about-cancer/treatment/drugs/ceritinib NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html ceritinib https://rxnav.nlm.nih.gov/id/rxnorm/1535457 Protein Data Bank in Europe (PDBe) http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/4MK PubChem https://pubchem.ncbi.nlm.nih.gov RCSB Protein Data Bank (RCSB PDB) https://www.rcsb.org/pages/policies https://www.rcsb.org/ Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=38061572-901764023 Thieme Chemistry LICENSE The Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated. https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=38061572-901764023 Wikidata LICENSE CCZero https://creativecommons.org/publicdomain/zero/1.0/ Ceritinib https://www.wikidata.org/wiki/Q21011233 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html ceritinib https://www.ncbi.nlm.nih.gov/mesh/67586847 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Antineoplastic Agents https://www.ncbi.nlm.nih.gov/mesh/68000970 Protein Kinase Inhibitors https://www.ncbi.nlm.nih.gov/mesh/68047428 KEGG LICENSE Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license https://www.kegg.jp/kegg/legal.html Therapeutic category of drugs in Japan http://www.genome.jp/kegg-bin/get_htext?br08301.keg USP drug classification http://www.genome.jp/kegg-bin/get_htext?br08302.keg Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg Drug Classes http://www.genome.jp/kegg-bin/get_htext?br08332.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html PATENTSCOPE (WIPO) SID 402615742 https://pubchem.ncbi.nlm.nih.gov/substance/402615742 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout Show More